Sandra Pohlman

Ms. Pohlman has an international client base, which she advises on all aspects of patent protection and litigation in her field, with her particular focus in the areas of molecular biology, antibodies, immunology, pharmaceutical agents and formulations, DNA/RNA based therapeutics and diagnostics, CRISPR, second medical uses and dosing regimens. A main part of her practice is oppositions and prosecution before the European Patent Office, where she has consistently obtained favorable results for her clients.

She has served as lead counsel in notable opposition cases relating to patents for blockbuster drugs and groundbreaking technologies, including, more recently, Tecfidera, Tysabri®, and attacking and defending CRISPR patents, as well as numerous antibody-related oppositions (adalimumab, Herceptin, bevacizumab, pertuzumab and nivolumab). Ms. Pohlman handles prosecution in the pharmaceutical and biotechnology fields for more than two decades and can deliver complex portfolio strategies that add value. She is consistently recognized as a leading attorney in her field, including consistent recognition in IAM1000 and as a Managing Intellectual Property (MIP) Star and MIP Top 250 Women in IP, as well as in Chambers and Juve. In 2022, MIP awarded her Attorney of the Year for patent matters in Germany and in 2024, her EPO opposition team received the prestigious award for European Cross-Border Patent Litigation Team of the Year for the matter of Tecfidera versus generics.

AIPLA

Sandra Pohlman is co-founder and partner of df-mp. She co-heads the firm’s large and diversified biotechnology and pharmaceuticals practice group. Ms. Pohlman has specialized in intellectual property in the biotechnology and pharmaceutical field since 1992. Ms. Pohlman’s qualifications enable her to represent clients before the European Patent Office, the UPC and German courts, and the U.S. Patent & Trademark Office.